Comparative antianaerobic activity of BMS 284756.
Agar dilution MIC methodology was used to compare the activity of BMS 284756 with those of ciprofloxacin, levofloxacin, moxifloxacin, trovafloxacin, amoxicillin-clavulanate, piperacillin-tazobactam, imipenem, clindamycin, and metronidazole against 357 anaerobes. Overall, the respective MICs at which 50% of the isolates tested were inhibited (MIC(50)s) and MIC(90)s (in micrograms per milliliter) were as follows: BMS 284756, 0.5 and 2.0; ciprofloxacin, 2.0 and 16.0; levofloxacin, 1.0 and 8.0; moxifloxacin, 0.5 and 4.0; trovafloxacin, 0.5 and 2.0; amoxicillin-clavulanate, 0.5 and 2.0; piperacillin-tazobactam, 0.25 and 8.0; imipenem, 0.06 and 1.0; clindamycin, 0.25 and 8.0; and metronidazole, 1.0 and >16.0. BMS 284756 is a promising new quinolone with excellent antianaerobic activity.
Hoellman
D B
DB
Departments of Pathology and Clinical Microbiology, Hershey Medical Center, Hershey, Pennsylvania 17033, USA.
Kelly
L M
LM
Jacobs
M R
MR
Appelbaum
P C
PC
D000890:Anti-Infective Agents / Q000494:pharmacology*; D001421:Bacteria, Anaerobic / Q000187:drug effects* / Q000201:enzymology; D019818:Clavulanic Acid / Q000494:pharmacology; D004352:Drug Resistance, Microbial; D004791:Enzyme Inhibitors / Q000494:pharmacology; D024841:Fluoroquinolones; D007211:Indoles; D008826:Microbial Sensitivity Tests; D015363:Quinolones; D065093:beta-Lactamase Inhibitors
D000890:Anti-Infective Agents; D004791:Enzyme Inhibitors; D024841:Fluoroquinolones; D007211:Indoles; D015363:Quinolones; D065093:beta-Lactamase Inhibitors; D019818:Clavulanic Acid; C419689:garenoxacin